Mannkind corp (MNKD)
Balance Sheet / TTM
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17Dec'16Sep'16Jun'16Mar'16Dec'15Sep'15Jun'15Mar'15Dec'14Sep'14Jun'14Mar'14Dec'13Sep'13Jun'13Mar'13Dec'12Sep'12Jun'12Mar'12Dec'11Sep'11Jun'11Dec'10
ASSETS
Current assets:
Cash and cash equivalents

38,868

29,906

30,173

7,968

34,530

71,157

10,446

26,178

26,706

43,946

20,092

43,384

47,978

22,895

35,530

63,733

27,653

59,074

32,928

107,187

120,844

120,841

172,465

41,214

35,759

70,790

93,803

28,529

28,005

61,840

1,765

31,639

56,355

2,681

22,786

24,770

66,061

Restricted cash

316

316

316

5,316

527

527

527

527

527

4,409

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Short-term investments

0

19,978

19,885

24,909

24,764

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Accounts receivable, net

5,032

3,513

4,093

4,974

3,759

4,017

2,752

2,848

1,550

2,789

1,804

1,312

438

302

3,137

-

144

-

1,679

4,748

4,282

50,436

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Receivable from Sanofi

-

-

-

-

-

-

-

-

-

-

-

-

-

30,557

-

-

-

23

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Inventory

3,231

4,155

3,692

3,963

3,720

3,597

2,785

3,676

3,891

2,657

3,129

3,172

3,698

2,331

5,124

2,866

-

-

23,402

19,816

16,789

9,670

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Asset held for sale

-

-

-

-

-

-

-

-

-

-

-

-

-

16,730

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Deferred costs from commercial product sales

-

-

-

-

-

-

-

-

-

405

543

500

472

309

279

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Deferred costs from collaboration

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

22,742

13,539

13,539

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

State research and development tax credit exchange receivable - current

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

803

-

-

-

298

450

450

450

-

-

-

-

765

0

674

Available-for-sale securities and certificate of deposit

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

350

350

350

-

513

497

4,370

Prepaid expenses and other current assets

1,901

2,889

3,584

2,704

2,392

2,556

3,015

2,570

2,354

3,010

3,061

2,563

3,508

4,364

4,534

1,423

2,807

4,018

13,227

14,076

16,375

20,206

20,253

3,696

3,640

5,485

5,228

3,183

3,830

4,520

21,082

18,356

3,004

3,140

2,960

1,593

2,849

Total current assets

49,348

60,757

61,743

49,834

69,692

81,854

19,525

35,799

35,028

57,216

28,629

50,931

56,094

77,488

48,604

90,764

44,143

76,654

71,236

145,827

158,290

201,153

193,521

44,910

39,399

76,275

99,329

32,162

32,285

66,810

23,197

50,345

59,709

5,821

27,024

26,860

73,954

Property and equipment, net

26,517

26,778

27,126

27,146

25,750

25,602

25,632

26,036

26,481

26,922

27,374

27,920

28,482

28,927

46,825

47,422

48,033

48,749

191,408

193,868

193,454

192,127

190,923

183,533

176,337

176,557

177,829

179,567

182,290

183,961

186,611

189,159

190,916

193,029

196,374

200,383

202,356

Right-of-use and other assets

-

-

6,271

4,815

5,519

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

State research and development credit exchange receivable - net of current portion

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

311

260

463

380

298

223

470

391

313

293

658

565

473

386

885

629

Deferred product costs from collaboration

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

13,539

10,831

6,251

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Other assets

4,347

6,190

-

-

-

249

199

320

368

437

480

523

609

648

702

1,248

1,096

1,009

1,831

2,025

2,027

848

2,114

7,400

8,437

5,516

10,227

230

230

230

230

230

230

230

230

230

317

Total assets

80,212

93,725

95,140

81,795

100,961

107,705

45,356

62,155

61,877

84,575

56,483

79,374

85,185

107,063

96,131

139,434

93,272

126,412

278,014

352,551

360,022

394,439

386,818

236,306

224,553

258,646

287,608

212,429

215,196

251,314

210,331

240,392

251,420

199,553

224,014

228,358

277,256

LIABILITIES AND STOCKHOLDERS' DEFICIT
Current liabilities:
Accounts payable

6,731

4,789

11,664

7,533

6,978

5,379

5,815

9,237

4,976

6,984

5,283

6,541

1,519

3,263

5,093

2,849

582

15,599

4,444

5,190

3,302

7,394

17,389

5,086

3,638

3,860

7,786

5,419

3,604

4,555

3,166

5,817

2,661

4,624

1,598

1,600

3,294

Accrued expenses and other current liabilities

18,326

15,904

14,298

16,452

18,064

15,022

13,434

14,075

15,930

12,449

12,492

9,076

10,657

7,937

14,164

10,252

8,077

7,929

14,081

13,930

12,381

26,206

27,269

20,579

15,006

21,634

21,553

26,984

26,379

25,777

48,598

49,624

31,746

20,736

15,715

19,958

14,840

Facility financing obligation

-

-

-

8,974

11,385

11,298

14,202

38,002

43,654

52,745

57,942

57,484

71,795

71,339

70,888

75,452

75,010

74,582

74,163

73,757

73,368

72,995

-

37,744

-

102,300

-

-

-

-

-

-

-

-

-

-

-

Short-term note payable

5,101

5,028

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Senior convertible notes - current

-

-

2,520

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

64,123

99,593

99,355

99,120

-

-

-

114,897

114,744

114,593

114,443

-

-

-

-

-

-

-

Deferred sales from collaboration

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

26,882

17,680

-

17,474

13,404

7,050

436

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Deferred revenue, net

-

-

-

-

-

-

-

-

-

3,038

3,021

2,592

1,844

3,419

2,014

135,229

134,935

-

157,145

171,850

185,059

196,967

150,000

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Deferred revenue — current

30,840

32,503

32,212

32,370

32,384

36,885

-

-

-

250

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Deferred payments from collaboration - current

-

-

-

-

-

-

10,095

396

250

-

250

250

250

1,000

462

-

-

140,231

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Deferred sales from collaboration

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

17,503

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Recognized loss on purchase commitments — current

7,250

7,394

3,593

11,649

9,057

6,657

16,081

13,191

15,859

12,131

12,480

9,926

6,984

5,093

8,340

20,986

12,927

12,475

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Warrant liability

-

-

-

-

-

-

-

-

-

-

-

-

-

-

4,871

18,056

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Share-based compensation liability

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

55,824

-

-

-

-

-

-

-

-

-

-

-

-

-

Note payable to related party

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

119,635

119,635

-

-

-

-

-

-

-

-

Total current liabilities

68,248

65,618

64,287

76,978

77,868

75,241

59,627

74,901

80,669

87,597

91,468

85,869

93,049

92,051

105,832

289,706

249,211

268,319

267,307

342,254

380,753

403,353

293,778

119,233

44,515

127,794

217,169

266,782

264,211

144,775

51,764

55,441

34,407

25,360

17,313

21,558

18,134

Promissory notes

70,022

70,020

70,019

-

-

72,089

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Accrued interest - promissory notes

-

-

807

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Note payable to related party

-

-

-

71,981

72,036

-

72,143

72,196

72,247

79,666

79,666

79,666

49,521

49,521

49,521

49,521

49,521

49,521

49,521

49,521

49,521

49,521

49,521

49,521

49,521

49,521

119,635

-

-

119,635

223,142

218,142

283,453

277,203

277,203

242,203

235,319

Accrued interest — promissory notes

3,259

2,002

-

9,132

7,969

6,835

5,692

4,566

3,469

2,347

1,173

-

9,995

9,281

-

-

-

6,380

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Long-term Midcap credit facility

38,893

38,851

38,798

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Facility financing obligation

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

72,625

-

25,871

-

72,933

-

-

-

-

-

-

-

-

-

-

Senior convertible notes

5,000

5,000

7,437

19,031

19,065

19,099

19,133

19,161

24,368

24,411

27,657

27,649

27,642

27,635

27,629

27,623

27,618

27,613

27,607

35,713

-

-

-

98,889

98,662

98,439

98,220

98,004

97,791

97,583

211,673

211,184

210,946

210,642

210,308

209,979

209,335

Sanofi loan facility and loss share obligation

-

-

-

-

-

-

-

-

-

-

-

-

-

-

71,210

69,978

68,835

62,371

43,653

28,415

-

3,034

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Recognized loss on purchase commitments — long term

82,987

84,639

85,858

81,978

85,344

91,642

84,362

88,346

96,694

97,585

99,769

99,001

95,062

95,942

63,229

52,515

55,605

53,692

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Operating lease liability

2,155

2,514

2,746

3,094

3,615

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Deferred revenue — long term

1,772

8,344

2,631

8,399

15,867

10,680

-

-

-

500

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Warrant liability

-

-

-

-

-

-

-

-

-

-

-

605

752

7,381

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Deferred payments from collaboration - long term

-

-

-

-

-

-

2,638

2,403

437

-

563

625

687

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Milestone rights liability

5,926

7,263

7,263

7,201

7,201

7,201

7,202

7,201

-

7,201

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Milestone rights liability

-

-

-

-

-

-

-

-

7,201

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Milestone rights liability and other liabilities

-

-

-

-

-

-

-

-

-

-

7,202

7,202

7,202

8,845

-

-

-

8,845

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Other liabilities

-

-

-

-

-

-

-

-

-

-

-

-

-

-

17,397

16,668

15,946

-

14,495

12,123

26,779

12,301

11,572

15,040

14,319

13,605

20,306

-

-

-

-

-

-

-

-

-

-

Total liabilities

278,262

284,251

279,846

277,794

288,965

282,787

250,797

268,774

285,085

299,307

307,498

300,617

283,910

290,656

334,818

506,011

466,736

476,741

402,583

468,026

457,053

468,209

427,496

282,683

207,017

289,359

455,330

364,786

362,002

361,993

486,579

484,767

528,806

513,205

504,824

473,740

462,788

Commitments and contingencies

-

-

-

-

-

-

0

0

0

-

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

Stockholders' deficit:
Undesignated preferred stock, $0.01 par value — 10,000,000 shares authorized; no shares issued or outstanding as of March 31, 2020 and December 31, 2019

-

-

-

-

-

-

0

0

0

-

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

Common stock, $0.01 par value - 280,000,000 shares authorized, 213,137,684 and 211,787,573 shares issued and outstanding at March 31, 2020 and December 31, 2019, respectively

2,131

2,118

2,064

1,894

1,878

1,870

1,594

1,456

1,260

1,192

1,047

1,046

958

957

4,784

4,777

4,290

4,287

4,182

4,121

4,090

4,061

4,055

3,964

3,869

3,697

3,100

3,012

2,894

2,860

1,998

1,993

1,678

1,315

1,313

1,309

1,278

Additional paid-in capital

2,801,044

2,799,278

2,790,890

2,769,396

2,765,020

2,763,067

2,723,232

2,698,028

2,658,957

2,638,992

2,570,072

2,566,960

2,554,230

2,553,039

2,548,090

2,546,727

2,510,367

2,508,633

2,457,482

2,434,777

2,424,347

2,416,967

2,413,621

2,371,487

2,362,129

2,261,996

2,072,006

2,036,640

1,996,185

1,991,379

1,774,893

1,763,939

1,694,658

1,620,535

1,616,981

1,614,018

1,587,858

Accumulated other comprehensive loss

-

-19

-20

-19

-19

-19

-18

-18

-15

-18

-20

-21

-24

-24

-21

-21

-19

-20

-19

-20

-21

-14

-11

-4

-4

-4

-9

-8

-8

-6

-8

-9

-3

44

45

38

74

Accumulated deficit

-3,001,225

-2,991,903

-2,977,640

-2,967,270

-2,954,883

-2,940,000

-2,930,249

-2,906,085

-2,883,410

-2,854,898

-2,822,114

-2,789,228

-2,753,889

-2,737,565

-2,791,540

-2,918,060

-2,888,102

-2,863,229

-2,586,214

-2,554,353

-2,525,447

-2,494,784

-

-

-

-2,296,402

-

-

-

-

-

-

-

-

-

-

-

Deficit accumulated during the development stage

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

2,458,343

2,421,824

2,348,458

-

2,242,819

2,192,001

2,145,877

2,104,912

2,053,131

2,010,298

1,973,719

1,935,546

1,899,149

1,860,747

1,774,742

Total stockholders' deficit

-198,050

-190,526

-184,706

-195,999

-188,004

-175,082

-205,441

-206,619

-223,208

-214,732

-251,015

-221,243

-198,725

-183,593

-238,687

-366,577

-373,464

-350,329

-124,569

-115,475

-97,031

-73,770

-40,678

-46,377

17,536

-30,713

-167,722

-152,357

-146,806

-110,679

-276,248

-244,375

-277,386

-313,652

-280,810

-245,382

-185,532

Total liabilities and stockholders' deficit

80,212

93,725

95,140

81,795

100,961

107,705

45,356

62,155

61,877

84,575

56,483

79,374

85,185

107,063

96,131

139,434

93,272

126,412

278,014

352,551

360,022

394,439

386,818

236,306

224,553

258,646

287,608

212,429

215,196

251,314

210,331

240,392

251,420

199,553

224,014

228,358

277,256